CD63 and Dna Mismatch Repair Protein Expression in Prostate Cancer

Simple item page
dc.contributor.authorFolkmanis, Kristofs
dc.contributor.authorEglītis, Jānis
dc.contributor.authorJakubovskis, Māris
dc.contributor.authorLietuvietis, Vilnis
dc.contributor.authorFolkmane, Inese
dc.contributor.authorIsajevs, Sergejs
dc.contributor.institutionRīga Stradiņš University
dc.date.accessioned2022-02-02T05:55:01Z
dc.date.available2022-02-02T05:55:01Z
dc.date.issued2021-06-01
dc.descriptionPublisher Copyright: © 2020 Kristofs Folkmanis et al., published by Sciendo.
dc.description.abstractProtein expression levels in immunohistochemistry and molecular biomarkers have been reported for their ability to predict recurrence, progression, development of metastases, and patient survival. The molecular features in low- and high-grade prostate cancer can differ and influence treatment decision and prognosis. The objective of the current study was to compare the expression of exosomal biomarkers CD63 and mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) by immunohistochemistry (IHC) in tissue of patients with prostate cancer and benign hyperplasia. Altogether, 62 patients with prostate acinar adenocarcinoma and 20 patients with prostate benign hyperplasia were enrolled in this retrospective study. CD63, MSH2, MSH6, MLH1, and PMS2 expression was analysed by immunohistochemistry. The obtained results showed that CD63 expression was significantly higher in patients with Grade III-V prostate cancer compared to Grade I-II, respectively; 2.23 (1-3) vs 0.92 (0-2) score, p = 0.001. In addition, a significant positive correlation between CD63 expression and grade groups was revealed (Rho = +0.54; p < 0.0001). Furthermore, progression-free survival was significantly higher in patients with low CD63 expression, compared to high CD63 expression (p = 0.0007). MMR expression was absent in 14 patients (four patients with Grade I-II cancer and 10 patients with Grade III-cancer). MMR was present in all cases of benign prostate hyperplasia (mild to moderate staining). The conclusion was that high grade prostate cancer (Grade groups III-V) was characterised by increased CD63 expression, which correlated with progression-free survival.en
dc.description.statusPeer reviewed
dc.format.extent6
dc.format.extent997169
dc.identifier.citationFolkmanis, K, Eglītis, J, Jakubovskis, M, Lietuvietis, V, Folkmane, I & Isajevs, S 2021, 'CD63 and Dna Mismatch Repair Protein Expression in Prostate Cancer', Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, vol. 75, no. 3, pp. 180-185. https://doi.org/10.2478/prolas-2021-0027
dc.identifier.doi10.2478/prolas-2021-0027
dc.identifier.issn1407-009X
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/7423
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85115614539&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofProceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbenign prostate hyperplasia
dc.subjectCD63 exosomal biomarker
dc.subjectimmunohistochemistry
dc.subjectmismatch repair pathway deficiency
dc.subjectmismatch repair protein biomarkers
dc.subjectprostate acinar adenocarcinoma
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral
dc.subjectSDG 3 - Good Health and Well-being
dc.titleCD63 and Dna Mismatch Repair Protein Expression in Prostate Canceren
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
CD63_and_Dna_Mismatch_Repair_Protein_Expression_in_Prostate_Cancer.pdf
Size:
973.8 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure